Note: You clicked on an external link, which has been disabled in order to keep your shopping session open.
|Tested species reactivity||Human, Mouse, Rat|
|Host / Isotype||Rabbit / IgG|
|Immunogen||Synthetic phosphopeptide derived from human Cot around the phosphorylation site of Threonine 290|
|Purification||Antigen affinity chromatography|
|Storage buffer||PBS, pH 7.2|
|Contains||0.05% sodium azide|
|Storage Conditions||Store at 4°C short term. For long term storage, store at -20°C, avoiding freeze/thaw cycles.|
|Tested Applications||Dilution *|
|Immunohistochemistry (Paraffin) (IHC (P))||1:50-1:200|
|Western Blot (WB)||1:500-1:1000|
* Suggested working dilutions are given as a guide only. It is recommended that the user titrate the product for use in their own experiment using appropriate negative and positive controls.
This antibody detects endogenous protein at a molecular weight of 53 kDa.
Purity is >95% by SDS-PAGE.
The role of mitogen-activated protein kinases (MAPKs) in cell signaling pathways is well established. The rat gene Tpl-2, for tumor progression locus 2, and the human and mouse homologues c-Cot, for cancer osaka thyroid oncogene, encode a proto-oncogene serine/threonine protein kinase that was shown to play a role in the functional activation of the MAP kinase pathway. Overexpression of Cot induces MAP kinase activation in COS-1 and NIH/3T3 cells. Cot-mediated activation of MAP kinase is inhibited by both Ras N17, a dominant negative mutant of c-H-Ras, and Raf-1s621A, a dominant negative mutant of Raf-1, suggesting that Cot functions upstream of Ras and Raf-1.Other studies have shown that a kinase-negative, dominant negative mutant of Cot partially blocks Ras or Raf-1-induced MAP kinase activation, arguing that Cot functions downstream of Ras and Raf-1.
For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.
augmented in rheumatoid arthritis 2; Cancer Osaka thyroid oncogene; cancer Osaka thyroid, oncogene; CCOT; cot (cancer Osaka thyroid) oncogene; COT proto oncogene serine/threonine protein kinase; COT proto-oncogene serine/threonine-protein kinase; EST; ESTF; Ewing sarcoma transformant; FLJ10486; M3K8; MAP3K 8; MAP3K8; mitogen activated protein kinase kinase kinase 8; Mitogen-activated protein kinase kinase kinase 8; Proto-oncogene c-Cot; proto-oncogene serine/threoine protein kinase; serine/threonine kinase (Tpl-2); Serine/threonine-protein kinase cot; TPL 2; TPL-2; TPL2; Tumor progression locus 2
AURA2; c-COT; COT; Cot/Tpl2; D17TPL2; EST; ESTF; MAP3K8; MEKK8; Tpl-2; TPL2